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ABSTRACT
PURIFICATION AND CHARACTERIZATION OF THE PROSTATE
CANCER-ASSOCIATED ANTIGEN: 7E11-C5

Qi Feng
Eastern Virginia Medical School
and
Old Dominion University
August, 1991
Director: George L. Wright, Jr., Ph.D.

A murine monoclonal antibody (MAb), designated 7E11-C5,
described by Horoszewicz et al. (Anticancer Res 7:927-936,
1987), recognizes a prostate organ-specific antigen.

This

MAb was generated against an established human prostate
adenocarcinoma cell line, LNCaP.

i:L1ln-labeled 7E11-C5 MAb

has been shown to localize specifically in LNCaP tumors
grown in nude mice (Lopes et al-, Cancer Res 50:6423-6429.
1990).

The objectives of the present study were to further

determine the specificity of the target 7E11-C5 antigen, and
to purify and biochemically characterize the antigen.
Under reducing conditions, the 7E11-C5 antigen
exhibited a major 100-Kd and a minor 70-Kd band, suggesting
that the antigen consisted of two peptide chains.

These two

bands were detected in tissue extracts of LNCaP xenografts,
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benign prostatic hyperplasia (BPH) and prostate carcinomas.
Similar bands were also detected in pooled normal seminal
plasma.

The bands were not identified in any of the non

prostate tissue extracts tested.

Competitive binding

experiments showed that antibodies to other prostateassociated antigens were unable to block the binding of
7E11-C5 MAb to its target antigen.

The molecular weight

comparison by Western blot demonstrated that there was no
similarity between the 7E11-C5 antigen and three major
prostate-associated markers: prostatic acid phosphatase
(PAP), prostate specific antigen (PSA) and prostate
secretory protein (PSP).

These results together strongly

indicated that the 7E11-C5 antigen was distinct from other
known major prostate antigens.
The 7E11-C5 antigen was purified 400-fold from LNCaP
xenograft tissue homogenate by immunoaffinity chromatography
with an estimated antigen recovery of 64%.

High pressure

liquid chromatography (HPLC) molecular exclusion column was
used to further purify the antigen and results showed that
the molecular weight of the 7E11-C5 antigen, under native
conditions, was about 500-Kd.

Biochemical characterization

of the 7E11-C5 antigen showed that the antigen was sensitive
to both periodate oxidation and protease treatment, thus
indicating that the antigen was a glycoprotein and that both
carbohydrate and peptide were required for antigenicity.
The antigen was found to be sensitive to pH 2.0, while
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remaining unaffected after treatment with NaOH (pH 11.0),
sodium dodecyl sulfate (SDS) or 2-mercaptoethanol.
Glycosidase treatment and lectin competitive binding
experiments suggested that the carbohydrates involved in the
antigenic determinant were galactose and N-acetyl-Dgalactosamine, although carbohydrate competitive binding
experiments showed that free carbohydrates or carbohydrate
conjugates were unable to block the antigen-binding site of
the 7E11-C5 MAb.

The 7E11-C5 antigen was not demonstrable

in thin-layer chromatography (TLC) immunoblot analysis of
glycolipid extracts of LNCaP tissue.
Western blot analyses of 48 serum samples from agematched normal males, BPH patients and prostate cancer
patients (stages A, B, c and D) failed to clearly show the
presence of the 7E11-C5 antigen in the serum samples.
Likewise, the 7E11-C5 antigen was not detected in these sera
using a competitive binding inhibition assay.

These results

suggest that the antigen is either not shed into the
circulation or that the antigen is either masked by serum
inhibitors or disassociated into fragments not recognized by
the 7E11-C5 MAb.
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CHAPTER I

INTRODUCTION

A.

REVIEW OF THE LITERATURE
Carcinoma of the prostate (CaP) is the most common male

malignancy in the United States.

Approximately one out of

eleven men will develop CaP at some time during their life
time, and the incidence of this disease is steadily
increasing.

Preceded only by lung cancer, CaP ranks as the

second leading cause of death by cancer among the U.S. male
population.

By the end of 1991, it has been estimated that

over 122,000 newly diagnosed cases of CaP and more than
32,000 deaths from this disease will be reported in the
United States (1, 2).
The CaP patient 5-year survival rate varies with the
clinical stage of CaP when diagnosed.

The survival rate is

85% for stage A (microscopic), 77% for stage B
(macroscopic), 65% for stage C (macroscopic and
extracapsular) and only 29% for stage D (metastatic).
Because localized CaP rarely causes symptoms, metastases
have already occurred in the majority of cases when first
diagnosed.

Therefore, one of the major problems with

diagnosis of CaP is that there is no reliable procedure that
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can detect early localized disease; a disease which is
curable with current treatments (3, 4).
One approach to aid in early diagnosis and in
monitoring the effectiveness of therapy has been the search
for specific prostate tumor markers.

There have been a

number of studies in which prostate organ-specific markers,
although not tumor-specific, have demonstrated their
usefulness for these purposes (5-7).

Two such markers,

prostatic acid phosphatase (PAP) and prostate specific
antigen (PSA), have become available for clinical use.
Currently, testing patient serum PAP and PSA levels,
especially PSA, is utilized both as part, of the clinical
routine follow-up studies or as a regular guide to
therapeutic decisions (8, 9).
Since 1938, when the association of elevated serum acid
phosphatase and advanced-stage CaP was first described by
Gutman et al. (10), serum PAP measurements have proven
useful, in some instance, in both the diagnosis of CaP and
in determining response to therapy.

PAP is a monoester

phosphohydrolase present in large quantities as an exocrine
secretion of the prostate.

However, it has been shown that

although serum PAP levels become elevated with extracapsular
growth of CaP in 24-71% of patients, in most patients with
early disease the serum PAP concentration is within the
normal range, thereby precluding use of this marker for
screening high-risk individuals.

While PAP levels have
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limited application as an early screening measure, these
values appear more useful in determining response to
therapies (11, 12).
Prostate specific antigen (PSA) was identified in 1979
and was shown to be produced exclusively by epithelial cells
of the prostate.

PSA antigen has been purified and found to

have a molecular weight of 34-Kd; also it has been shown to
consist of a single peptide chain containing about 7%
carbohydrates (13-15).

Serum PSA levels in both benign

prostatic hyperplasia (BPH) and in CaP patients have been
shown to be significantly elevated as compared with those in
normal males or males with non-prostate cancer.

Although no

quantitative difference in serum PSA levels has been found
between BPH patients and patients with CaP stage A and stage
B, patients with stage C or stage D exhibited significantly
elevated PSA levels.

Serum PSA values in CaP patients were

found to be valuable in predicting survival time, monitoring
clinical course and early recurrence of CaP.

High PSA

levels in Cap patients are correlated with poor prognosis
and, in post-operative monitoring, strongly suggest disease
recurrence.

Compared with PAP, PSA appears to be more

specific and valuable in the diagnosis and prognosis of CaP
(16-21).
One report suggests that the simultaneous measurement
of both PAP and PSA in serum can be of added value in
diagnosis of CaP (22).

However, even in this study, only
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58% of the CaP patients with stage A and B disease had
elevated levels of either or both markers, while 10% of the
BPH patients had positive serum levels for these markers.
In summary, PAP and PSA are prostate organ-specific antigens
and the assays developed to detect PAP or PSA have limited
use in early diagnosis since they can not differentiate
early CaP from BPH (23).
The analysis of human prostatic fluid proteins has
shown that another abundant 16-Kd protein, prostate
secretory protein (PSP), is present in addition to PAP and
PSA (24-28).

This 94-residue peptide has been estimated to

represent at least 20% of the proteins in normal prostate
fluid.

This protein has been detected in prostate tissue as

well as in the serum and urine from CaP patients, suggesting
that this protein might be a useful marker for the diagnosis
and prognosis of CaP (29-31).
In addition to the three prostate tumor-associated
markers described above, many others have been identified by
various investigators.

Ware et al. (32) described a

monoclonal antibody (MAb), alpha Pro3, produced against the
CaP cell line PC3.

This MAb reacted with normal prostate,

BPH and tumors of other organs as well as CaP.

Webb et al.

(33) generated another MAb, alpha Pro5, against a different
epitope of the alpha Pro3 antigen.

In another study,

Frankel et al. (34) using BPH tissue as an immunogen,
generated a group of prostate-organ specific MAbs.

Starling
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et al. (35) generated a MAb, D83.21, by using the CaP cell
line DU145 as an immunogen.

The MAb displayed preferential

binding to prostate and bladder cancer cell lines and
tissues, and the D83.21 antigen was characterized as a
membrane glycoprotein with 28-60 Kd subunits.

Another MAb

described by the same group, designated Turp-27 (36, 37), is
reactive to a prostate-associated antigen, but also cross
reacts with central nervous system tissues and peripheral
nerves.

Both Raynor et al. (38) and Carroll efc al. (39)

have used the CaP cell line PC-3 to generate murine MAbs.
However, the MAbs reacted with normal prostate, BPH, and
other cancer cell lines as well as CaP.

Bazinet et al*

(40)

reported two MAbs that recognized the same 58-Kd protein
selectively expressed by CaP epithelial cells but not by
benign prostate tissue or other normal tissues.

Recently,

Kim et al. (41) described MAb PR92, which is reactive with
CaP, breast and lung cancer cell lines, but not with normal
and other cancer cell lines.

Another MAb generated in our

laboratory (42), designated PD-41, was found to react to 60%
of CaP by immunohistological staining, and to bind minimally
to normal prostate and BPH tissues.

The PD-41 target

antigen appears to be a mucin-like glycoprotein.

Table I

summarizes the prostate-associated markers discussed above,
including the 7E11-C5 antigen which is the subject of the
present study.
A murine MAb, 7E11-C5 (IgGl, k) , was described by
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TABLE I
Summary of Prostate-Associated Markers
Marker

nature

MW (Kd)

Ref.

specificity

PAP

gpa

45-50b

organ

11, 12

PSA

gp

34

organ

13-16

PSP

gp

16

organ?

24-27

Turp-27

gp

35-310

organ

36, 37

KR-P8

gp

48-75

organ

38

alpha Pro3

gp

54

organ?

32

alpha Pro5

gp

54

organ?

33

o•

organ?

39

F77-129
D83.21

gp

28-60

organ?

35

P25.48

gp

58

CaP?

40

P25.91

gp

58

CaP?

40

PR92

gp

44

CaP?

41

PD-41

gp

90-400

CaP?

42

7E11-C5

gp

70, 100

organ

43, 46

a glycoprotein.
13 All molecular weights were determined under reducing
conditions.
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Horoszewicz et al. in 1987 (43).

This MAb was generated

against an established human prostate adenocarcinoma cell
line, LNCaP (44, 45) and is reactive with an insoluble,
cytoplasmic fraction of the LNCaP cells.

111In-labeled

7E11-C5 MAb was recently shown to specifically localize in
LNCaP tumors grown in nude mice (46).
prostate organ-specific antigen.

The MAb recognizes a

The specificity of 7E11-C5

was observed to be restricted to human prostatic epithelial
cells, including normal prostate, BPH, and CaP.

Except for

LNCaP, none of the 32 lines of human normal or non-prostate
neoplasms reacted with MAb 7E11-C5.

In a survey of frozen

sections from 175 human specimens, it was reported that
positive immunoperoxidase staining was limited to the
epithelium in all 11 specimens of localized and metastatic
CaP, 7 BPH and 7 normal prostates.

None of the 26 various

non-prostatic tumors nor 120 out of 122 specimens from 28
different normal organs were reactive.

Using a crude

competitive binding enzyme linked imraunoabsorbent assay
(ELISA), Horoszewicz et al. reported the presence of
circulating 7E11-C5 antigen in 20 out of 43 sera from CaP
patients.

None of 30 normal blood donor sera nor 7 BPH sera

were positive (43).

The ELISA results suggested that the

antigen was shed in sera of advanced-stage CaP patients (43,
46).

If these results, particularly the serum data, can be

confirmed with a refined immunoassay, this antigen/antibody
system might have potential usefulness for diagnosis or
prognosis of CaP.
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B. FOCUS OF THE PRESENT INVESTIGATION
Although the preliminary ELISA results suggest the
7E11-C5 antigen could be detected in the serum samples of
advanced-stage CaP patients, no further reports from the
same laboratory have been published and their experiments
have not been confirmed independently.

Therefore, the

sensitivity, specificity and reproducibility of these
results remain uncertain.

The biological function of the

antigen, the nature of the antigen and the relation of this
antigen to the other prostate-associated antigens also
remain unknown.

The objectives of this study are:

1. To purify the 7E11-C5 antigen using LNCaP xenograft
tissues as the antigen source.

Unlike the other prostate

proteins, this antigen is an insoluble cytoplasmic molecule,
therefore, before chromatography procedures can begin, the
antigen must first be converted into a soluble form by
detergents.

Various approaches including several

chromatography procedures, such as molecular exclusion, ion
exchange, immunoaffinity and high pressure liquid
chromatography (HPLC), would be applied to purify the
antigen and a solid-phase radioimmunoassay used to determine
activity of the antigen.
2. To understand the nature of the antigen.

The

purified antigen would be used to immunologically and
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biochemically characterize the antigen.

In general, the

naturally occurring antigens are proteins or carbohydrates,
and carbohydrates may be present as part of the antigen in
the form of a glycoprotein or glycolipid.

Protein antigens

are likely to be sensitive to protease treatments, while
carbohydrate antigens are likely to be sensitive to
periodate oxidation treatment which destroys carbohydrate
residues.

Carbohydrate components can be further identified

using enzymatic deglycosylation and lectin competitive
binding experiments.
3.

To evaluate the potential usefulness of the 7E11-C5

antigen/antibody system as an adjunct in diagnosis or
prognosis of CaP.

First, serum samples from age-matched

normal males, BPH and CaP patients (stages A, B, C and D)
would be evaluated for presence of the 7E11-C5 antigen by
Western blot, in order to verify the previous report that
the antigen was shed in the sera of advanced-stage CaP
patients.

Secondly, an immunoassay would be developed to

detect the antigen in the serum samples.

The results from ’

7E11-C5 serum assay would be compared with results from
serum PSA (currently, the most commonly used CaP marker in
clinic application) in order to determine whether the 7E11C5 antigen level in the serum would provide any additional
diagnostic or prognostic information for CaP.
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CHAPTER II

MATERIALS AND METHODS

A.

MATERIALS
1. Tumor tissue and antibodies:

The LNCaP nude mouse

xenograft tissues (stored in RPMI-1640 medium and kept in
-20*c) and the 7E11-C5 MAb (IgGl, k), purified by Protein-A
chromatography from mouse ascites fluid, were provided by
CYTOGEN Corporation (Princeton, NJ).

Several other murine

MAbs which were specific to the different prostateassociated markers, including anti-PAP (IgG2a), anti-PSA
(IgGl), anti-PSP (IgGl), Turp-27 (IgG3), PD-41 (IgGl) and
Leu-7 (IgM), were obtained from the Department of
Microbiology and Immunology, Eastern Virginia Medical School
(EVMS).

Antibody concentrations were determined using a

single radial immunodiffusion system (TAGO, Burlingame, CA).
Normal mouse IgGl, IgG2a, IgG3 and IgM (Bionetics,
Charleston, SC) were used as controls.

Affinity purified

rabbit anti-mouse IgG (H+L) polyclonal antibodies (Jackson,
West Grove, PA) were labeled with

an<j usea as the

secondary antibody in radioimmunoassay.
2. Chromatography columns, chemicals, enzymes, lectins,
carbohydrates, organic solvents and radio-isotopes:
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a. Columns: Molecular exclusion, ion exchange,
immunoaffinity and high pressure liquid chromatography
(HPLC) columns, including Sephadex G-100, Sephadex G-200,
Sephacryl S-300, DEAE-Sepharose CL- 6 B (Pharmacia,
Piscataway, NJ), ImmunoPure Ag/Ab Immobilization Kit #1
(Pierce, Rockford, IL) and HPLC molecular exclusion column
(Bio-Sil Sec-250, BioRad, Richmond, CA), were used for
purification of the 7E11-C5 antigen .
b. Chemicals:

Detergents, Nonidet P-40 (NP-40), 3-[(3-

cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS,
Sigma, St. Louis, MO) and Octyl-beta-glucoside (Glucoside,
Boehringer Mannheim, West Germany) were used to solubilize
the LNCaP tissue extracts.

Chemicals, including periodate

(NaI04 , Mallinckrodt, Paris, KY) , sodium dodecyl sulfate
(SDS) and 2-mercaptoethanol (BioRad), were used to
characterize the antigen.

Chloramine T (Eastman Kodak,

Rochester, NY), sodium metabisulfite and sodium iodide
(Mallinckrodt) were used for the antibody iodination.
c. Enzymes:

Enzymes, including trypsin type III,

alpha-chymotrypsin, protease type XIV, protease type XXI,
protease type XXVI, neuraminidase, beta-galactosidase,
chondroitinase ABC, Endo-beta-N-acetyl-glucosaminidase F
(Endo F), alpha-L-fucosidase (Sigma), O-glycanase and Nglycanase (Genzyme, Boston, MA) were used to characterize
the antigen.
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d. Lectins:

Lectins (E. Y., San Mateo, CA) were used

to determine the carbohydrate specificity of the antigen,
including Concanavalia ensiformis (Con A), Griffonia
simplicifolia II (GS II), Triticum vulgaris (WGA), Dolichos
biflorus (DBA), Glycine max (SBA), Arachis hvoogaea (PNA),
Maclura pomifera (MPA), Ulex europaeus I

(UEA I), Limulus

polvphemus (LPA) and Phaseolus vulgaris (PHA).
e. Carbohydrates and carbohydrate conjugates:
Carbohydrates and carbohydrate conjugates, including
melibiose, lactose, L-fucose, D-mannose, N-acetyl-Dgalactosamine (galNAc), N-acetylglusosamine (glcNAc, E. Y.),
D-glucose (Mallinckrodt), D-galactose, D-raffinose,
stachyose, 2-acetamido-2-deoxy-3-0-beta-D-galactopyranosylD-galactopyranose and N-acetyllactosamine (Sigma) were used
to characterize the antigen.
f. Organic solvents:

Organic solvents used to

characterize the antigen included chloroform, aqueous
phenol, formic acid, pyridine (Fisher, Fair Lawn, NJ),
acetic acid (Mallinckrodt), formamide (BRL, Gaithersburg,
MD), dimethylformamide, n-butanol (Sigma), and methanol
(Quantum, Tuscola, IL).
g. Radio-isotopes:

Sodium-125I (Na-125I, ICN, Irvine,

CA), specific activity 40 mCi/ml, was used for antibody
iodination and 35S-methionine (Amersham, Arlington Heights,
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IL), specific activity 5.58 mCi/ml, was used for metabolic
labeling of the antigen.
3. Serum samples:

Serum samples and relevant clinical

information were provided by the Serum/Tissue Bank of the
Department of Microbiology and Immunology, EVMS.

All

patients were previously untreated when the sera were
donated.

Serum samples were stored at -70*C until used.

The PSA results for these samples, using Tandem-R PSA
immunoradiometric assay (Hybritech, San Diego, CA), were
provided by the Clinical Immunology Laboratory, Department
of Microbiology and Immunology, EVMS.

B.

METHODS
1.

LNCaP cell culture.

LNCaP cultured cell line,

obtained from American Type Culture Collection (ATCC,
Rockville, MD), was maintained in RPMI-1640 medium (Sigma)
supplemented with

10%

heat inactivated bovine calf serum

(HyClone, Logan, UT), 1 nM dihydrotestosterone, 1 mM Lglutamine and 50 pq/ml gentamicin (Sigma).

The culture was

kept in a humidified atmosphere of 5% CO2 in air at 37 *C
(44-48).

The cells were transferred at weekly intervals

using simple dispersing by pipetting or

0

.0 1 %

(ethylenedinitrilo)-tetraacetic acid disodium salt (EDTA,
Mallinckrodt) in phosphate-buffered saline (PBS, 136 mM
NaCl, 2.7 mM KC1,

8

mM Na 2 HP04 , 1.5 mM KH 2 PO4 , 0.9 mM CaCl2 ,

0.5 mM MgCl2 , pH 7.4).
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2. Tissue extracts.

Tissue extracts of the LNCaP

xenograft tumor were prepared by first finely mincing the
tissue in 10 ml of 1.0 mM NaHC0 3 buffer containing 200 /j1 of
a 50 x protease inhibitor cocktail (antipain 1.7 mg,
pepstatin 5.0 mg, EDTA 186 mg dissolved in 10 ml distilled
water).

The tissue was then homogenized in the buffer by a

Polytron homogenizer (Brinkman, NY).

The homogenate was

spun at 2 x 103 g, 4 ‘C for 5 minutes, and the supernatant
was further spun at 1.38 x 105 g, 4*C for 2 hours.

The

resulting pellet was resuspended in a minimum volume of PBS
and stored at ~70*C (37, 49, 50).

This pellet, membrane-

enriched fraction, was the antigen-enriched preparation and
was used for purification of the 7E11-C5 antigen.

Protein

concentrations were determined by a bicinchoninic acid (BCA)
protein assay (Pierce) with bovine serum albumin (BSA,
Sigma) as the standard (51) and the 7E11-C5 antigen activity
was determined by radioimmunoassay.
3. Antibody iodination.

The antibodies, including

rabbit anti-mouse IgG (H+L) polyclonal antibody and 7E11-C5
MAb, were labeled with 125i using the chloramine T method
(52, 53).

Briefly, 10 (il of Na-125I in 0.01 N NaOH

(approximately 250 nCi) were neutralized with the same
volume of 0.01 N HC1 in a tube.

To this solution was added

20 jil PBS and 122.5 fiq antibody in 50 fil PBS.

The reaction

was initiated with 21.6 /xl of freshly prepared chloramine T
(4 mg/ml).

The mixture was allowed to incubate for 1 minute
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with gentle shaking.

At this point, 90 pi sodium

metabisulfite (2.4 mg/ml) was added to the mixture and
incubated for 10 seconds.

The reaction was then quenched

with 180 fil sodium iodide (10 mg/ml).

The reaction mixture

was transferred to a Ultrafree-MC filter unit (Millipore,
Bedford, HA) for membrane ultrafiltration in order to
separate bound versus unbound label.

The reaction mixture

was transferred to the upper chamber of the filter and the
filter was centrifuged at 2 x 103 g for 25 minutes.

The

upper chamber was then transferred to a fresh
microcentrifuge tube and the volume of the filtrate was
determined.

An aliquot of PBS, equal to the filtrate

volume, was added to the concentrate to initiate the wash
steps.

This procedure was repeated twice.

After the final

wash, the concentrate was measured for retained volume and
transferred to a storage tube.

The entire iodination

procedure was performed at room temperature.

Total

radioactivity was then counted and trichloroacetic acid
(TCA, Hallinckrodt) precipitation assay was carried out to
determine the
procedure,

100

1 2 5 I-antibody

Ml of

1

coupling efficiency.

For this

:1 , 0 0 0 diluted labeled antibody

solution were incubated with an equal volume of 20% TCA for
15 minutes at 4 ’C.

After centrifuging for

10

minutes,

radioactivities of the supernatant and diluted sample were
determined and the TCA precipitation percent was calculated
using the following formula:
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precipitation %

total sample cpm - supernatant cpm
------------------------------------- x
total sample cpm

100

For both antibodies, the TCA precipitation percents were
usually over 85%.
4.

Radioimmunoassay.

The 7E11-C5 antigen preparation

was added to the wells of a 96-well microtiter plate (Becton
Dickinson, Oxnard, CA) at 3-5 /xg protein/25 /xl/well.

The

plate was air-dried and fixed with 50 jxl of PBS containing
0.1% glutaraldehyde (Fisher) for 5 minutes and blocked with
50 /xl of normal saline containing 10% normal horse serum and
0.1% sodium azide for at least l hour.

Primary antibody,

7E11-C5 MAb (20 /ig/ml), was added at 25 /xl/well, and the
plate was incubated for 1 hour.

The unbound MAbs were

removed by washes with washing buffer (normal saline
containing

1%

normal horse serum and

The secondary antibody,

1 2 5 I-labeled

0

.1 % sodium azide).

rabbit anti-mouse IgG

(H+L) , was added at 105 counts per minute (cpm)/25 jxl/well
and the plate was incubated at room temperature for another
hour.

The unbound labeled antibodies were removed by

washing three times with the washing buffer.

The plate was

air-dried, the wells were cut, and the radioactivity was
measured in a gamma-counter (36).

Culture supernatant from

P3X63Ag8, a non-IgG-secreting subclone of the murine myeloma
cell line (54), was used as a negative control and all tests
were performed at least in duplicate.
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5. Antigen solubilization.

The tissue extracts (3.5

mg/ml) were treated with three detergents, including NP-40,
CHAPS and Glucoside at different concentrations, for 1 hour
at 4*C.

The sample was spun at 105 g, 4'C for 1 hour, and

the supernatant and pellet harvested.

The protein

concentration was determined by the BCA protein assay and
the antigen activity was determined by radioimmunoassay.
One unit of antigen was defined as lo4 cpm (55-59).

6

. Molecular exclusion chromatography.

Three molecular

exclusion columns were evaluated for separating the antigen
from contaminating materials, including Sephadex G-100 with
a fractionation range of molecular weight (MW) 4,000150,000, Sephadex G-200 with a range of MW 5,000-600,000,
and Sephacryl S-300 with a range of MW 10,000-1,500,000.
The detergent solubilized LNCaP tissue extracts (2.12.6

mg/ml) were loaded on the column and the sample volumes

were always less than 5% of the column bed volume.

The

running buffer was 10 mM Tris-HCl, pH 7.5, 145 mM NaCl and
flow rate was controlled by using a peristaltic pump (ISCO,
Lincoln, NE).
4 *C.

All column procedures were carried out at

Protein concentrations of the collected fractions were

determined by UV 280 nm absorbance and the antigen activity
was assayed by radioimmunoassay (60).
7. Ion exchange chromatography.

A DEAE-Sepharose CL-6 B

column was equilibrated with 10 mM Tris-HCl buffer, pH 7.8
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and 20 ml of solubilized LNCaP tissue extract (4.6 mg/ml)
was loaded onto the column.

After the sample entered the

column, the column was washed with
equilibrating buffer.

1

bed volume of

The elution conditions were as

follows: 10 mM Tris-HCl, pH 7.8, 0.08 M NaCl followed by 10
mM Tris-HCl with a 0.08 M to 0.2 M NaCl gradient, pH 7.8,
and a final elution buffer of 10 mM Tris-HCl, pH 7.8
containing 1.0 M NaCl.

The fractions were collected and

measured for protein concentration by absorption at OD 280
nm and the antigen activity for selected fractions (protein
peaks and shoulders) were tested by radioimmunoassay.

The

entire procedure was carried out at 4*C (31, 61).

8

. Immunoaffinity chromatography.

a. Elution buffer:

Screening for a suitable elution

buffer was performed using a modified radioimmunoassay to
test antigen stability in elution buffer.

One hundred

microliters of test buffer were added to the wells of 96well antigen-coated plate and incubated for
temperature.

PBS was used as control.

2

hours at room

The plate was then

subjected to a standard radioimmunoassay with the 7E11-C5
MAb as primary antibody.

Percent of antigen stability for

each buffer was calculated using the following formula:

% Ag stability

cpm from buffer treated wells
----------------------cpm from PBS treated wells

x 100

To determine the efficiency of test buffer in
disassociating the antibody/antigen binding, 25 ^1 of 7E11-

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited w ithout p erm ission.

19

C5 MAb (20 /ig/ml) was added to the 7E11-C5 antigen coated
wells and incubated for 1 hour and washed.
100

The test buffer,

/il/well, was then added to the wells and incubated for

hours.

PBS was used as the control.

times with washing buffer, the

2

After washing three

1 2 5 I-labeled

secondary

antibody (rabbit anti-mouse IgG) was added and incubated for
another 1 hour.

The radioactivity was determined after

washing three times and the antigen elution percent for each
buffer was calculated using the following formula:

% Ag elution = (1

cpm from buffer treated wells
-----------------------) x 100
cpm from PBS treated wells

b. Column preparation:

An ImmunoPure Ag/Ab

immobilization Kit #1 column was used and the 7E11-C5 MAbmatrix coupling protocol was performed according to the
manufacturer's instructions.

Briefly, the 2 ml-column was

prepared by equilibrating the gel with

6

ml of coupling

buffer (0.1 M phosphate, pH 7.0, 0.05% sodium azide), then
the bottom of column was sealed, and 2 ml of the 7E11-C5 MAb
solution

(10

mg/ml) were added to the equilibrated column.

The reducing reagent, 200 /il of 6.4% sodium cyanoborohydride
(NaBH3 CN) in 0.01 N NaOH, was added to the column.

The

column was sealed and mixed by gentle up-down shaking for
hours at room temperature.

The reaction was then allowed to

proceed for another 4 hours without shaking.

The effluent

was collected and the column was washed with 4 ml of the
coupling buffer.

2

The wash buffer was combined with the
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effluent and used to determine the coupling efficiency.

The

column was then equilibrated with 4 ml of quenching buffer
(1.0 M Tris-HCl, pH 7.4) and sealed.

The quenching buffer

(2.0 ml) and 200 fil of the reducing buffer (6.4% N a B ^ C N in
0.01 N NaOH) were added and the gel was mixed again by
gentle shaking for 30 minutes at room temperature, followed
by washing with 20 ml of washing buffer (1.0 M NaCl) and 20
ml of storage buffer (0.05% sodium azide).

The column was

stored at 4*C with the storage buffer (62).
c. Antigen purification:

After the 2 ml immunoaffinity

column was equilibrated with running buffer (normal saline),
1 ml of the solubilized LNCaP tissue extracts (4.2 mg/ml)
was allowed to enter the gel and the column was sealed and
incubated at room temperature for 1 hour.
then washed with

20

ml

(10

The column was

column bed volumes) of running

buffer to remove nonspecific molecules.

Eight microliter (4

bed volume) of the elution buffer (2.0 M MgCl 2 , pH 5.6) were
then used to elute the antigen from the column.

The

fractions collected were monitored for protein by OD 280 nm
absorbance and tested for the 7E11-C5 antigen activity by
radioimmunoassay using the elution buffer as a control (6366 ).
9.

HPLC.

Before HPLC fractionation, the antigen

positive fractions collected from the immuoaffinity column
were pooled and dialysed against HPLC running buffer (normal
saline) overnight at 4°C.

The sample was then concentrated
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by membrane ultrafiltration using Centriprep-30 concentrator
(MW 30,000 cut-off, Amicon, Beverly, MA).

Some samples also

were concentrated by an absorption method (67,

68

).

The

sample was placed in dialysis tubing which was then placed
in a dry bed of high molecular weight polyethylene glycol
(PEG, MW 8,000, Sigma) until concentration was completed.
After the HPLC gel filtration column was equilibrated with
running buffer,

2

ml of the desalted and concentrated sample

(30 /ig/ral) prepared as described above were applied to the
column.
nm.

The protein concentrations were monitored at OD 280

The peak fractions were tested by radioimmunoassay for

antigen activity and the HPLC running buffer was used as
control (69).

A flow chart for purifying the 7E11-C5

antigen is shown in Figure 1.
10. Peptide Sequencing.

The HPLC purified 7E11-C5

antigen samples were sent to the Protein and Nucleic Acid
Sequencing Center at the University of Virginia,
Charlottesville, VA. for determination of N-terminal amino
acid sequence and amino acid composition of the antigen
using a gas-phase sequencer (70).
11. Chemical and enzyme treatment.

The 7E11-C5 antigen

(LNCaP tumor tissue extracts or the immunoaffinity purified
antigen) were treated with different chemicals and enzymes
at varying concentrations in an Eppendorf tube for 24 hours
at 37*C and then used to coat wells of microtiter plates.
PBS or relevant buffers were used as controls.
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Figure 1. Procedure for the 7E11-C5 Antigen Purification

LNCaP xenograft tissue
Homogenate
I
Centrifugation, 2 x 103 g, 5 minutes, 4*C
I
Supernatant

i
Centrifugation, 1.38 x 105 g, 2 hours, 4 ’C
Pellet
I
Solubilization with 1% NP-40, 1 hour, 4'C

i
Centrifugation, 105 g, 1 hour, 4*C
Supernatant
Immunoaffinity chromatography
I
Desalt by dialysis
I
Concentration
HPLC
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Radioimmunoassay was performed to determine the remaining
antigen activity following each treatment.

Percent control

binding for each treatment was calculated using the
following formula:

% control binding

cpm of the reagent treated wells
----------------------------------- x
cpm of the PBS treated wells

100

Selected samples were also analyzed by Western blot in
order to confirm the radioimmunoassay results (65,
12.

Competitive antibody binding assay.

66

, 71).

Varying

concentrations (0 - 1 0 0 /xg/ml) of unlabeled antibody (blocking
antibody) were added, 25 /xl/well, to the purified antigencoated wells and incubated for

2

hours at room temperature.

The blocking antibodies used were murine MAbs reactive with
different prostate-associated antigens.

These MAbs included

anti-PAP, anti-PSA, anti-PSP, Turp-27, PD-41 and Leu-7 (72,
73).

The controls included PBS, unlabeled 7E11-C5 MAb, and

normal murine IgGl, IgG2a, IgG3 and IgM.

The

125

I-labeled

7E11-C5 MAb (test antibody), at 50% maximal binding
activity, was then added to the wells (5 x 105 cpm/25
Ail/well) and incubated for another 2 hours.

After washing

three times with washing buffer, the radioactivity in the
wells was determined.

The percent inhibition was calculated

using the following formula (31):

% Inhibition = (1

cpm of blocking antibody wells
-------------------------------- ) x 100
cpm of PBS wells
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13. Lectin competitive binding assay.

Lectins were

diluted to a concentration of 1.0 mg/ml in PBS, as suggested
by the manufacturer, for maximal activity.

Each lectin (100

^ 1 /well) was added to purified antigen-coated wells and
incubated for 2 hours with PBS as control.

After washing

the wells three times, a standard radioimmunoassay was
performed using 50% maximal binding titer of 7E11-C5 MAb as
the primary antibody, and the percent control binding was
calculated using the following formula (37):

% control binding

cpm of the lectin treated well
--------------------------------- x
cpm of PBS treated wells

100

A radioimmunoassay using 7E11-C5 MAb as the primary
antibody, directed against lectin-coated wells, was carried
out to determine whether or not the 7E11-C5 MAb was reactive
to the lectin.
14. Carbohydrate competitive binding assay.

Varying

concentrations of carbohydrates, carbohydrate conjugates or
PBS (control) were incubated with an equal volume of 7E11-C5
MAb in Eppendorf tubes for 2 hours at room temperature.
Following the incubation, 50 /il of this mixture was added to
antigen-coated wells and incubated for 1 hour.
three washes,

125

Following

I-labeled rabbit anti-mouse IgG was added

as in a standard radioimmunoassay.

The percent control

binding for each carbohydrate was calculated using the
following formula (37):

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited w ithout p erm ission.

25

% control binding

15.

cpm of carbohydrate treated wells
---------------------------------- x
cpm of PBS treated wells

100

Sodium dodecyl sulfate-polyacrylamide gel

electrophoresis (SDS-PAGE) and Western blot analysis (7477).

SDS-PAGE was performed using a 160 x 180 x 1.5 mm gel

(4% stacking and 10%
sample buffer (0.5 M

resolving).Samples were dilutedwith
Tris-HCl, pH

6

.8 , 2% SDS,5% 2-

mercaptoethanol, 10% glycerol, 0.05% bromophenol blue),
heated at 100*C for 5 minutes and
100 fig protein/lane.

loaded onto the gel, 60-

The gel was run at 40 mA constant

current for 5 hours at 4*C with running buffer (Tris base 12
g, glycine 57.6 g, SDS 4 g to 4,000 ml dH 2 0 ) .

Molecular

weight protein standards (Amersham) were used as a reference
for migration of proteins and included myosin (MW 200,000),
phosphorylase b (MW 92,500), BSA (MW 69,000), ovalbumin
(46,000), carbonic anhydrase (MW 30,000), trypsin inhibitor
(MW 21,500) and lysozyme (MW 14,300).

The separated

proteins were electrophoretically transferred to Immobilon-P
PVDF (polyvinylidene difluoride) transfer membrane
(Millipore) at 25 Volts, 4*C for 11 hours with transferring
buffer (Tris base 15.15 g, glycine 72 g to 5,000 ml cH^O).
Following transfer of the proteins, the membrane was blocked
with 100 ml of PBS containing 5% BSA and 0.3% Tween-20 for 1
hour at 37“C.

The membrane was then incubated with 100 ml

of 7E11-C5 MAb (20 /ig/ml) for 2 hours at room temperature
with gentle agitation, followed by washing three times in
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PBS containing 0.05% Tween-20.
with

1 2 5 I-labeled

cpm/ 1 0 0 ml for

1

After subsequent incubation

rabbit anti-mouse IgG (H+L) at 1 x 107
hour and further washing three times, the

membrane was air-dried and exposed to X-ray film (Eastman
Kodak) at -70*C for one to four days.
16. Silver stain (78, 79).

Following SDS-PAGE, the gel

was fixed with 200 ml of 50% methanol containing 0.1%
formaldehyde (Sigma) for 2 hours or overnight.

The gel was

then incubated with 200 ml of 0.005% dithiothreitol (DTT,
Sigma) for 45 minutes, followed by incubation with 200 ml of
0.5% silver nitrate (Sigma) for another 45 minutes.

The

color was developed using 200 ml of 3% sodium carbonate
(Mallinckrodt) containing 0.05% formaldehyde (freshly
prepared).

When the color developed to the desired point,

it was stopped with 25 ml of 2.3 M citric acid (Sigma).

The

gel was washed three times with water and stored in water.
The entire procedure was performed at room temperature and
the gel was gently agitated during all incubations.
17. Glycolipid extracts.

Glycolipid extractions from

LNCaP tissue were carried out according to the method
introduced by Clark et al. (80).

Briefly, under oxygen

exclusion conditions, the LNCaP tissue homogenate was
treated with protease type XIV (10 mg/ml) and detergent
(0.1% NP-40) at 55°C for 24 hours.

The sample was then

separated into phases by adding chloroform and methanol to
obtain a final ratio of chloroform/methanol/buffer of

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited w ithout p erm ission.

27

4: 8 :5.6 (v/v/v).

The mixture was centrifuged at 3 x 103 g

for 10 minutes and the upper layer was saved.

The lower

layer was treated with chloroform and methanol, and
centrifuged again.

The procedure resulted in the pooled

upper layer fraction containing glycolipids with longer
oligosaccharide chains (> 5 monosaccharides) and organic
solvents, and the lower layer fraction containing
glycolipids with shorter oligosaccharide chains (< 5
monosaccharides) and detergent.

The upper layer was then

evaporated with nitrogen, dissolved in methanol/water (1 :1 ,
v/v) and applied to a Sep-Pak column (Ciq cartridges,
Millipore) to separate the upper phase glycolipids from
contaminating peptides, glycopeptides and salts.

The lower

layer was also evaporated with nitrogen, dissolved in
chloroform and applied to a silica gel column (Silicic Acid,
Bio-Sil A, 20-44 microns, BioRad) to separate the
glycolipids from the contaminating detergent.

The separated

upper layer and lower layer samples were evaporated with
nitrogen and then dissolved in chloroform/methanol (1 :1 ,
v/v) separately.

The glycolipid samples (the upper layer

and the lower layer) were used as targets in
radioimmunoassay and for TLC and TLC immunoblot.

The

concentration of the glycolipids was determined by phenolsulfuric acid assay.
sample were mixed with

For this procedure, 100 fil of test
6

jil of 90% phenol and 500 nl

sulfuric acid, and the absorbance of the mixture was
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measured at OD 495 nm.

Varying concentrations of D-glucose

were used for generating a standard curve.
18. Thin-layer chromatography (TLC) and TLC immunoblot
analysis (81).

The extracted glycolipid samples (20

Mg/lane) were carefully loaded on a TLC plate (TLC aluminium
sheets silica gel 60, 10 x 10 cm, West Germany) and the
plate was placed in tank containing a solvent system
consisting of chloroform/methanol/water (5:4:1, v/v/v).

The

solvent was allowed to migrate to the top of the plate
(approximately

1

hour), the plate was removed and air-dried.

The plate was either visualized or further analyzed by
immunoblot.

To visualize the glycolipid bands on TLC, the

plate was evenly sprayed with orcinol-H2 S0 4 reagent (0 . 2 g
orcinol in 11 ml sulfuric acid and 89 ml ethanol) and then
activated by heating at 100*C for 5 minutes.

Glycolipids

gave pinkish violet bands on a white background.

The

procedure for the TLC immunoblot was the same as that for
Western blot analysis described previously.

Twenty

micrograms of gangliosides (type II, purified from bovine
brain, Sigma) were used as standard controls (82), and
included at least 4 molecules, trisialoganglioside lb (G<nb#
MW 2,100), monosialoganglioside 1 (Gjq, MW 1,540),
sphingomyelin (MW 600) and N-acetylneuraminic acid (MW 309).
19. Antigen immunoprecipitation (83-85).

The spent

medium from LNCaP cells cultured in a 75-cm2 tissue culture
flask was removed and the cells were washed once with
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methionine-free RPMI-1640 medium (Sigma).

The methionine-

free medium (5.0 ml) was added to the culture and incubated
at 37°C overnight.

After exchanging the medium for fresh

methionine-free medium, 250 uci

3 5 S-methionine

was added to

the culture and incubated at 37*C for 6-18 hours.

The cells

were then harvested and lysed with lysis buffer (145 mM
NaCl, 0.5% NP-40, 50 mM Tris-HCl, pH 8.0).

The cell lysate

was collected and spun at 105 gr, 4*C for 30 minutes and the
resulting supernatant was harvested.

7E11-C5 MAb (20 /ig/ml)

was added to the supernatant (50 /il MAb/ml supernatant) and
the mixture was incubated at 4*C for 1 hour to form an
immune complex.

To purify the immune complex, 10% Protein-A

Sepharose CL-4B (Sigma) was added to the mixture (50 /il/ml)
and the sample was kept at 4*C for 30 minutes.

After

washing three times with lysis buffer, the final pellet was
treated with SDS-PAGE sample buffer, boiled, and analyzed by
10% SDS-PAGE.

The gel was then dried and autoradiography

was carried out as described previously.

Normal mouse IgGl

was used as a control antibody.
20.

Western blot analysis of serum samples.

Serum

samples from six categories, including normal males, BPH
patients (biopsy proven) and CaP patients (stages A, B, c
and D, biopsy proven) were analyzed by SDS-PAGE and Western
blot.

Since CaP is uncommon in men younger than age 50,

normal serum samples were obtained from donors over 50 years
of age (4).

Eight serum samples were selected from each
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category and 4 /il of serum/lane was loaded onto the SDS-PAGE
gel.

LNCaP tissue extract, 80 /xg/lane, was used as a

positive control.

The electrophoresis and blotting

procedures were the same as described previously.

The

labeled 7E11-C5 MAb was used for antigen detection and

IOC

125

i-

labeled normal mouse IgGl used as control.
21.

Competitive inhibition assay.

One hundred

microliters of test serum sample were incubated with an
equal volume of 7E11-C5 MAb at room temperature for 3 hours.
The MAb concentration was diluted to 50% of maximal binding
as determined by previous binding tests.

A diluent buffer,

PBS containing 0.3% BSA, was used as a control.

The mixture

(50 jxl/well) was then added to the wells of 96-well plate
coated with the purified 7E11-C5 antigen.
incubated at 4'C for 18 hours.
with washing buffer,

125

The plate was

After washing three times

I-rabbit anti-mouse IgG (H+L) was

added to the wells and incubated at room temperature for
hour.

The percent inhibition for each serum sample was

calculated using the following formula (43,

% Inhibition = (1

86

):

cpm of serum + 7E11-C5 MAb
-------------------------------) x 100
cpm of diluent + 7E11-C5 MAb

The serum samples used in this study included normal
female, normal male, BPH, all grades of CaP.

Two to five

serum samples were analyzed from each category.
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CHAPTER III

RESULTS

A.

Further determination of the specificity of the 7E11-C5

antigen.
1.

A previous immunohistochemical study demonstrated

that the 7E11-C5 antigen was prostate organ-specific (43).
In the present study, Western blot analysis of different
tissue extracts and normal seminal plasma showed that the
7E11-C5 antigen was only detected in the tissue extracts of
LNCaP (the immunogen for generating the hybrid secreting
7E11-C5 MAb), normal prostate, BPH, CaP and normal seminal
plasma, but not in tissue extracts of normal lung, breast
cancer and colon cancer (Figure 2).

Under reducing

conditions, the 7E11-C5 antigen exhibited a major 100-Kd
band and a minor 70-Kd band.

Some samples of normal

prostate, BPH and CaP exhibited other high molecular weight
bands (Figure 2) (87,

88

).

Western blot analysis also

demonstrated that the 7E11-C5 MAb was not reactive with
purified PAP and PSA (Figure 2).

A nonspecific 55-Kd band

seen on the blot was identified as endogenous human IgG
heavy chain, because the rabbit anti-mouse antibody has
minimal cross-reaction with human immunoglobulins.
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Figure 2. Specificity of the 7E11-C5 MAb as determined by
Western blot analysis.

Different tissue extracts, normal

seminal plasma, and purified PAP and PSA antigens were
subjected to 4-20% linear gradient SDS-PAGE.

Tissue

extracts and seminal plasma were applied at 60 fig
protein/lane and purified antigen at

10

fig protein/lane.

The separated proteins were transferred to Immobilon-P
membrane, and then analyzed for reactivity with 7E11-C5 MAb.
SP, normal seminal plasma; NP, normal prostate; BP, benign
prostatic hyperplasia; CaP. carcinoma of prostate; LNX.
LNCaP xenograft tumor; PAP, purified PAP; PSA, purified PSA;
B, breast carcinoma; L, normal lung, C, colon carcinoma.
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2.

Competitive antibody binding results showed that

other antibodies (anti-PAP, anti-PSA, anti-PSP, Turp-27, PD41 and Leu-7)
125

(72, 73) were unable to block the binding of

I-labeled 7E11-C5 MAb to its target antigen (Figures 3,

4, 5).

Comparing the profiles of the 7E11-C5 antigen with

PAP, PSA and PSP antigens on Western blot, the 7E11-C5
antigen showed no similarity with these three major prostate
markers (Figure

6

).

These results together strongly

indicated that the 7E11-C5 antigen was an unique prostate
organ-specific antigen.

B.

Purification of the 7E11-C5 antigen (89).
1. Antigen solubilization.

Three detergents, CHAPS,

Glucoside and NP-40, were evaluated for their abilities to
solubilize the 7E11-C5 antigen from the LNCaP tissue
extracts.

The result showed that 0.5% and 1% of NP-40

appeared to be the best concentration for solubilizing the
antigen (Table II), resulting in both the highest per cent
recovery of protein in the supernatant as well as the
highest antigen activity.
2. Molecular exclusion chromatography.

Molecular

exclusion columns (Sephadex G-100, Sephadex G-200 and
Sephacryl S-300), separating molecules based on their sizes
and shapes, were evaluated for purifying the antigen.
7E11-C5 antigen activity appeared primarily in the void
volume, although the antigen activity shifted slightly
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Figure 3. Competitive binding radioimmunoassay of the 7E11C5 MAb to its target antigen with MAbs to PAP, PSA and PSP.
Varying concentrations (0-100 fxg/ml) of blocking antibodies,
including unlabeled 7E11-C5 MAb (IgGl), anti-PAP (IgG2a),
anti-PSA (IgGl) and anti-PSP (IgGl), were added to the
purified 7E11-C5 antigen-coated wells and incubated at room
1pc
temperature for 2 hours, followed by adding of the
labeled 7E11-C5 MAb (5 x 105 cpm/25 /il/well).

After

incubation for another 2 hours and three washes, the
radioactivity in the wells was determined.
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Figure 4. Competitive binding radioimmunoassay of 7E11-C5
MAb to its target antigen with MAbs to Turp-27, PD-41 and
Leu-7.

The procedure was the same as described in Figure 3

The blocking antibodies were murine MAbs Turp-27 (IgG3), PD
41 (IgGl), Leu-7 (IgM) and unlabeled 7E11-C5 MAb (IgGl),

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited w ithout p erm ission.

7E11—C5 Binding

35

• — • 7E11-C5
o — o Turp—27
a — a pd -41
a — a Leu-7
8060-

% Inhibition of

4020

-

0n-

-20
0

0.1

1

10

Competing Mab concentration (ug/m l)

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited without p erm ission.

100

Figure 5. Competitive binding radioimmunoassay of the 7E11C5 MAb to its target antigen with different isotype-matched
control murine antibodies.
described in Figure 3.

The procedure was the same as

The blocking antibodies were normal

mouse IgGl, lgG2a, IgG3, IgM and unlabeled 7E11-C5 MAb

(IgG l)•
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Figure 6. Comparison of the 7E11-C5 antigen with PAP, PSA
and PSP by Western blot analysis.

The samples were

subjected to 6-20% linear gradient SDS-PAGE and then
transferred to Immobilon-P membrane.

Lane 1 . LNCaP tissue

extracts, 100 fig; lane 2 . normal seminal plasma, 20 fig; lane
3., purified PSA, 7 fig, and lane 4 . purified PSP, 10 fig.

The

membrane was then cut into individual lanes and reacted with
different antibodies separately; 7E11-C5 MAb for lane 1,
anti-PAP MAb for lane 2, anti-PSA MAb for lane 3 and antiPSP MAb for lane 4.
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TABLE II
Comparison of Solubilization of the 7E11-C5 Antigen with
Different Detergents3

Detergent

Protein in
supernatant
(mg/ml)

%

Ag activity
(unit/mg)

Ag activity
(unit/ml)

PBS

0.5

-

20.0

9.9

10 mM CHAPS

1.3

27

30.7

39.9

20 mM CHAPS

1.4

30

23.3

32.6

30 mM Glucoside

1.35

28

57.7

77.8

0.5% NP-40

1.6

37

50.6

81.0

1% NP-40

1.5

33

65.0

97.5

10 mM CHAPS
30 mM Glucoside
0.5% NP-40

1.4

30

45.7

64.0

20 mM CHAPS
30 mM Glucoside
1% NP-40

1.35

28

29.4

39.7

a LNCaP tissue extract sample (3.5 mg protein/ml) was
treated with a single detergent or combination of detergents
at 4'C for 1 hour and spun at 105 g for 1 hour. Protein
concentration of the supernatant was determined by the BCA
protein assay. The 7E11-C5 antigen was tested by
radioimmunoassay and one unit of the antigen was defined as
10 cpm.
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beyond the void volume in Sephacryl S-300 separation,
suggesting that the antigen molecule scarcely entered the
pores of the gel matrices, even with the large fractionation
range of the Sephacryl S-300.

These results indicated that

molecular exclusion chromatography was not suitable as a
single step method for separating the 7E11-C5 antigen from
contaminating materials (Figures 7, 8, 9).
3. Ion exchange chromatography.

A DEAE-Sepharose CL-6B

column, separating molecules based on charge differences,
was used for purifying the 7E11-C5 antigen.

The results

(Figure 10) showed that the antigen was distributed widely
throughout the entire separation with low antigen activity
as compared with molecular exclusion chromatography.
4. Immunoaffinity chromatography.

An immunoaffinity

column was then used to purify the antigen as an alternative
to molecular exclusion or ion exchange chromatography.

The

7E11-C5 MAb and gel matrix coupling procedure was performed
according to the manufacturer's instructions with a coupling
efficiency over 80%.

The next step was to screen buffers

for the ability to elute the antigen from the column.
Modified radioimmunoassay procedures were used to test the
antigen stability in test buffer and the ability of the
buffer to disassociate the antigen/antibody binding.
Buffers with a high pH (pH 11.0) or a high salt
concentration appeared to be potential candidates for
antigen elution (Table III).

However, a small-scale trial
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Figure 7. Purification of the 7E11-C5 antigen by Sephadex G100.

The Column was Sephadex G-100, 22 x 0.8 cm, with

fractionation range (MW) of 4,000-150,000.

The loading

sample was 2.1 ml of solubilized LNCaP tissue extract (2.6
mg/ml) and the running buffer was 10 mM Tris-HCl, pH 7.5,
0.145 M NaCl with flow rate of 0.2 ml/minute.

Fractions

were collected at a volume of 1.5 ml/tube, the protein
concentration measured by absorbance at UV A 2 8 0

and

antigen reactivity determined by radioimmunoassay.
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Figure 8. Purification of the 7E11-C5 antigen by Sephadex G200.

The column was Sephadex G-200, 22 x 0.8 cm, with

fractionation range (MW): 5,000 - 600,000.

The loading

sample was 2.0 ml of solubilized LNCaP tissue extract (2.1
mg/ml) and running buffer was 10 mM Tris-HCl, pH 7.5, 145 mM
NaCl with flow rate of 0.2 ral/minute.

Fractions were

collected at a volume of 1.5 ml/tube, the protein
concentration measured by absorbance at UV A 2 8 O nm an(*
antigen reactivity determined by radioimmunoassay.
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Figure 9. Purification of the 7E11-C5 antigen by Sephacryl
S-300.

The column was Sephacryl S-300, 75 x 1.6 cm, with

fractionation range (MW): 10,000 - 1,500,000.

The loading

sample was 7.0 ml of solubilized LNCaP tissue extract (2.2
mg/ml) and running buffer was 10 mM Tris-HCl, pH 7.5, 0.145
M NaCl with flow rate: 0.6 ml/minute.

Fractions were

collected at a volume of 3.5 ml/tube, the protein
concentration measured by absorbance at UV A 2 8 O nitl and
antigen reactivity determined by radioimmunoassay.
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Figure 10. Purification of the 7E11-C5 antigen by ion
exchange chromatography.

The column was DEAE-Sepharose CL-

6B, 23 x 2.6 cm and loading sample was 20 ml of solubilized
LNCaP tissue extracts (4.6 mg/ml).

The equilibrating buffer

was 10 mM Tris-HCl, pH 7.8 and the elution buffer was 10 mM
Tris-HCl, pH 7.8, 0.08 M - 1.0 M NaCl gradient.

Flow rate

was 1.0 ml/minute and fractions were collected at a volume
of 3.0 ml/tube.

The protein concentration was measured by

absorbance at UV A 2 8 O nm and antigen reactivity determined
by radioimmunoassay.
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TABLE III
Screening Potential Elution Buffers for
Immunoaffinity Chromatography

Buffer

Ag stability3
(%)

Ag elution*1
(%)

o.l M glycine, pH 2.5

62

61

0.15 M Na-citrate, pH 3.0

67

56

0.1 M Tris-HCl, pH 11.0

100

87

0.1 M triethylamine, pH 11.5

100

89

25% glycerol, pH 8.0

100

7

10% dioxane

32

77

2.0 M NaCl

100

64

2.0 M HgCl2

99

96

4.0 M MgCl2

96

93

5.0 M LiCl

97

56

a One hundred microliters of test buffer were added to the
7E11-C5 antigen-coated wells and incubated at room
temperature for 2 hours. PBS was used as control. The well
was then washed and subjected to a standard radioimmunoassay
with 7E11-C5 MAb as the primary antibody.
k Twenty five microliters of 7E11-C5 MAb (20 /xg/ml) were
added to the antigen-coated wells, incubated at room
temperature for 1 hour and washed. Test buffer was then
added to the wells (100 ^1/well) and incubated for an
additional 2 hours. PBS was used as control. The well was
washed and 125I-labeled secondary antibody was added to the
wells. After washes, radioactivity remaining in the wells
was determined.
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showed that pH 11.0 buffers damaged the linkage of the
antibody to the gel matrix, resulting in MAb being washed
out of the column, while a buffer consisting of 2.0 M MgCl 2
proved to be able to effectively elute the antigen without
releasing the antibody (data not shown).
Figure 11 illustrates purification of the antigen by
immunoaffinity chromatography.

After the elution buffer was

added to the column, a small protein peak with high antigen
activity (cpm value > 7,000) was released from the column.
The purified antigen was desalted, concentrated and analyzed
by SDS-PAGE.

The Western blot and silver stain analyses of

the 7E11-C5 antigen before and after immunoaffinity
chromatography are shown in the Figure 12.

The results

confirmed that the 7E11-C5 antigen was successfully purified
by immunoaffinity chromatography (Figure 12 A, lane A and
B).

It was noticed that after purification, the molecular

weight profile of the antigen was changed, showing now that
the purified antigen exhibited 100-Kd and 45-Kd bands
instead of 100-Kd and 70-Kd bands.

One explanation for this

result might be that the high concentration of salt (2.0 M
MgCl2) degraded the antigen.

The blot also showed that

there was no antigen detected in the non-absorbed fraction
(Figure 12 A, lane C), indicating that the immunoaffinity
column efficiently bound the antigen molecules in the
loading sample.

PAGE silver stain analysis showed that

besides the 100-Kd band, there were several other protein
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Figure 11. Purification of the 7E11-C5 antigen by
immunoaffinity chromatography.

A 2 ml-column prepared from

an immunoPure Ag/Ab Immobilization Kit #1 was loaded with 1
ml of solubilized LNCaP tissue extract (4.2 mg/ml).

The

washing buffer was normal saline (145 mM NaCl, pH 7.0) and
the elution buffer was 2.0 M MgCl 2 , pH 5.6.

Flow rate was

0.6 ml/minute and fractions were collected at a volume of
1.0 ml/tube.

The protein concentration was measured by

absorbance at UV A 2 8 O nm anc* antigen reactivity determined
by radioimmunoassay.
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Figure 12. SDS-PAGE analysis of LNCaP tissue extracts and
the eluate from immunoaffinity column.

7E11-C5 antigen

containing samples were separated by 10% SDS-PAGE and then
the 7E11-C5 MAb reactive components determined by Western
blot analysis, protein identified following silver staining.
(A) Western blot:

lane A . solubilized LNCaP tissue extract,

60 nq; lane B . the eluate from immunoaffinity column, 10 yg;
lane C . the non-absorbed proteins from immunoaffinity
column, 60 /ig.

(B) Silver stain: lane A . molecular weight

markers (Kd)? lane B . solubilized LNCaP tissue extract, 60
jig? lane C . the eluate from immunoaffinity column, 10 f*g.
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bands (Figure 12 B, lane C), indicating that the purified
antigen was not totally pure.
A quantitative comparison (Table IV) showed that,
following the purification protocol, approximately a 400fold antigen purification from the LNCaP tissue homogenate
was achieved and approximately 64% of the antigen was
recovered.
5.

HPLC.

The eluate from the immunoaffinity column was

desalted, concentrated and further purified by HPLC
molecular exclusion.

Figure 13 shows that a single peak

with high antigen activity was eluted by HPLC.

Based on a

comparison with the standard controls, the molecular weight
of the peak corresponded to approximately 500-Kd, indicating
the molecular weight of 7E11-C5 antigen was about 500-Kd in
its native state.
The HPLC purified samples were analyzed by a gas-phase
sequencer for determination of N-terminal amino acid
sequence and amino acid composition of the antigen, but the
results were inconclusive because of the insolubility of the
antigen.

The sample requirements for the sequence analysis

are that protein must be pure, soluble and without any
contamination of detergents or salts.

A high percent (77%)

of the purified 7E11-C5 antigen becomes insoluble again
after removing the detergent during the desalting and
concentration procedures, resulting in a soluble protein
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TABLE IV
Purification of the 7E11-C5 Antigen from
LNCaP Tissue Homogenatear
Antigen
Total
Volume protein
Sample
(ml)
(mg)

Activity
(unit/mg
protein)

Fold
purifi
cation

Total
activity
(unit)

Recovery
(%)

lb

24

312

52

2

20

260

62

1.2

15,990

97.6

3

7

70

190

3.7

13,293

81.2

4

6

30

350

6.7

10,509

64.2

5

45

20,446

393

10,509

64.2

0.514

-

16,380

-

a Wet weight of the original LNCaP tissues was 2.4 g.
Protein concentrations were determined by the BCA protein
assay. The 7E11-C5 antigen was quantitated by
radioimmunoassay and one unit of antigen was defined as 10
cpm.
b 1, LNCaP tissue homogenate; 2, supernatant from the
first centrifugation; 3, pellet from the second
centrifugation; 4, supernatant from NP-40 solubilization; 5,
eluate from immunoaffinity column.
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Figure 13. Purification of the 7E11-C5 antigen by HPLC.

The

column was an HPLC molecular exclusion column, 300 x 7.5 mm
with fractionation range (MW) of 1,350-670,000.

The loading

sample was 2 ml of desalted and concentrated eluate from
immunoaffinity chromatography (12 fig/ml) and the running
buffer was normal saline (145 mM NaCl, pH 7.0).

Flow rate

was 1.0 ml/minute, protein concentration measured by
absorbance at UV A 2 8 O nm and antigen reactivity determined
by radioimmunoassay.
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concentration too low to effectively conduct the sequence
analysis (data not shown).

C.

Characterization of the 7E11-C5 antigen (89).
The 7E11-C5 antigen reactivity was tested after the

antigen was subjected to various treatments.

Both the

immunoaffinity purified antigen and the crude antigen (LNCaP
tissue extract) were used for this portion of the study and
the experiments were carried out using a modified
radioimmunoassay.
1. Physical and chemical treatment.

Table V showed

that although the antigen was resistant to 100*C for 10
minutes, it was sensitive to heating at 100*C for 1 hour, a
condition which severely denatures proteins.

Periodate

(NaI0 4 ) treatment, which oxidizes and cleaves sugar residues
from glycoproteins, reduced the 7E11-C5 antigen activity,
indicating that carbohydrate was involved in the antigenic
determinant.

The antigen activity remained unchanged after

treatment with SDS or 2-mercaptoethanol.

The antigen was

sensitive to acid conditions but resistant to basic
conditions.

These results were confirmed by Western blot

analysis (Figure 14).
2. Proteolytic treatment:

The 7E11-C5 antigen was

sensitive to all five proteases tested.

It was noticed that

there was a linear relationship between the concentration
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TABLE V
Physical and Chemical Treatment of the 7E11-C5 Antigen3

Treatment

Condition

% control binding13
crude Ag
pure Ag
94
20

NTC
4

5 mM
10 mM
20 mM

36
39
37

NT
NT
NT

1%
5%

140
98

113
112

2-mercaptoethanol

1.25%

94

93

HC1

0.1 N
1 N

47
38

NT
38

NaOH

0.1 N
1 N

100
139

91
99

heat
periodate

SDS

100*C, 10 minutes
100*C, l hour

3 For chemical treatment, the 7E11-C5 antigen activity was
tested by radioimmunoassay after the antigen was treated
with a chemical at 37*C for 24 hours. PBS was used as
control.
b crude Ag, LNCaP tissue extracts; pure Ag, immunoaffinity
purified antigen.
c NT, not tested.
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Figure 14. Western blot analysis: Chemical and enzyme
treatment of the 7E11-C5 antigen.

The 7E11-C5 antigen

(LNCaP tissue extract) was treated with various chemicals or
enzymes for 24 hours at 37*C and then subjected to 10% SDSPAGE, 80 /zg/lane, and Western blot.

Lane A . PBS control;

lane B . trypsin 100 U/ml; lane C . trypsin 1,000 U/ml; lane
D, chymotrypsin 0.5 U/ml; lane E . chymotrypsin 5 U/ml; lane
F, 0.1 N HC1, pH 2.0; lane G . 0.1 N HC1, pH 4.0; lane H . 0.1
N NaOH, pH 9.0; lane I . 0.1 N NaOH, pH 11.0; lane J . 2 mM
periodate; lane K . 20 mM periodate; lane L . protease XXI 4
mU/ml; lane M . protease XXI 40 mU/ml; lane N . protease XIV
0.01 mg/ml; lane O . protease XIV 0.1 mg/ml; lane P .
neuraminidase 0.01 U/ml and lane O . neuraminidase 0.1 U/ml.
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MW
Kd

100
70

A

B

C

D

E

F

G

H

1

J

K

L

M

N

O
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increase of the proteases tested and the decrease of the
remaining antigen activity (Table VI).

These results were

confirmed by Western blot analysis (Figure 14), strongly
indicating that protein played an important role in the
antigenic determinant.

The sensitivity of the 7E11-C5

antigen to both periodate oxidation and protease treatment
suggests that the antigen is a glycoprotein.
3. Glycosidase treatment.

Glycosidases hydrolyze

specific sugar residues from glycopeptides or glycoproteins.
Various glycosidase treatments were carried out to determine
the specificity of the carbohydrate involved in the 7E11-C5
antigenic determinant.

Table VII and Figure 15, lane B and

C showed that the antigen was sensitive to betagalactosidase.

Galactosidase catalyzes the release of

galactose residues from galactose conjugates, which suggests
that galactose is a major component of the antigenic
determinant.
4. Competitive binding experiments with lectins and
carbohydrates.

Lectins non-covalently bind to specific

carbohydrate groups.

The specificity of the carbohydrate

involved in the antigen epitope was tested by using various
lectins to block the binding of 7E11-C5 MAb to its target
antigen.

The results (Table VIII) showed that D-galactose-

binding lectins (MPA, PNA) and N-acetyl-D-galactosaminebinding lectins (DBA and SBA) reduced the binding of 7E11-C5
MAb to the target antigen, suggesting that galactose and
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TABLE VI
Proteolytic Enzyme Treatment of the 7E11-C5 Antigen3

Enzyme

Hydrolysis
specificity0

trypsin

Concentration

Lys, Arg

chymotrypsin

Tyr, Phe, Trp

protease XIV

broad spectrum

protease XXI

protease XXVII

casein

broad spectrum

% control binding*5
crude Ag pure Ag

U/ml
U/ml
U/ml
U/ml

NT
NT
NT
NT

95
84
32
11

5 mU/ml
50 mU/ml
500 mU/ml

NT
NT
NT

92
16
7

2 mg/ml

25

NT

2 mU/ml
20 mU/ml
200 mU/ml

98
66
17

87
70
18

8 mU/ml
80 mU/ml
800 mU/ml

NT
NT
NT

27
25
8

0.1
1
10
100

3 The 7E11-C5 antigen activity was tested by
radioimmunoassay after the antigen was treated with various
enzymes at 37*C for 24 hours. PBS was used as control.
b crude Ag, LNCaP tissue extracts; pure Ag, immunoaffinity
purified antigen.
° Lys, lysine; Arg, arginine; Tyr, tyrosine; Phe,
phenylalanine; Trp, tryptophan.
d NT, not tested.
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TABLE VII
Glycosidase Treatment of the 7E11-C5 Antigen3

Enzyme

Digestion
specificity0

neuraminidase
betagalactosidase

alpha-Lfucosidase
O-glycanase

N-glycanase
Endo F
chondroitinase
ABC

Concentration

NeuNAc
beta-Dgalactoside

Asn-linked sugars

chondroitin
A, B and C

115
108

mU/ml
mU/ml
mU/ml
mU/ml

136
112
73h
NT

115
101
80
63

50 mU/ml
500 mU/ml

NT
NT

98
96

5 mU/ml
10 mU/ml

97
101

103
100

1 U/ml
2 U/ml

93
100

97
101

5 mU/ml
50 mU/ml

100
96

108
112

5 mU/ml
50 mU/ml

81
NT

103
107

1
10
100
1, 000

gal-beta(1*3)-galNAc

keratin sulfate

97
100

0.1 U/ml
1 U/ml

P-n itropheny1
alpha-L-fucoside

% control binding*3
crude Ag pure Ag

3 The 7E11-C5 antigen activity was tested by a
radioimmunoassay after the antigen was treated with various
enzymes at 37*C for 24 hours. PBS was used as control. For
O-glycanase, beta-galactosidase and Endo F treatment, the
samples were pre-treated with neuraminidase (l U/ml) at 37*C
for 2 hours.
b crude Ag, LNCaP tissue extracts, pure Ag, immunoaffinity
purified antigen.
c NeuNAc, N-acetylneuraminic acid; Endo F, Endo-beta-Nacetylglucosaminidase F; Asn, asparagine.
^ NT, not tested.
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A

B
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D
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Figure 15. Western blot analysis: Enzymatic deglycosylation
of the 7E11-C5 antigen.

The 7E11-C5 antigen (LNCaP tissue

extract) was treated with various glycosidases at 37*C for
24 hours.

The samples were then subjected to 10% SDS-PAGE

gel (80 jig/lane), transferred to Immobilon-P membrane and
analyzed for reactivity with 7E11-C5 MAb.

lane A . PBS

control; lane B . beta-galactosidase 100 mU/ml; lane c . betagalactosidase 1,000 mU/ml; lane D . alpha-L-fucosidase 100
mU/ml; lane E . alpha-L-fucosidase 1,000 mU/ml.
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TABLE VIII
Competitive blocking of 7E11-C5 MAb Binding to
its Target Antigen with Lectins3

Lectin

Carbohydrate
specificity"

Percent
control binding

MPA

alpha-D-gal

27

PNA

D-gal-beta-(1-3)-D-galNAc

33

DBA

alpha-D-galNAc, D-gal

47

SBA

alpha-D-galNAc, D-gal

64

con A

alpha-D-man, alpha-D-glc

89

GS II

D-glcNAc

89

WGA

(D-glcNAc)2 , NeuNAc

90

UEA I

alpha-L-fuc

92

LPA

NeuNAc, D-galNAc, D-glcNAc

100

PHA

oligosaccharide

100

a One hundred microliters of competing lectin (1 mg/ml)
were added to purified antigen coated wells and incubated at
room temperature for 2 hours. PBS was used as control. A
radioimmunoassay was then performed using the 7E11-C5 MAb as
primary antibody.
b gal, galactose; galNAc, N-acetyl-D-galactosamine; man,
mannose; glc, glucose; glcNAc, N-acetyl-D-glucosamine; Fuc,
fucose; NeuNAc, N-acetyl-Neuraminic acid.
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N-acetyl-D-galactosamine (galNAc) are part of the antigenic
determinant.

A result from control experiment showed that

the 7E11-C5 MAb did not cross-react with the lectins (data
not shown).
Different carbohydrates and carbohydrate conjugates,
were tested for their ability to block the antigen-binding
site of the MAb 7E11-C5.

The results (Table IX) showed that

none of the carbohydrates or carbohydrate conjugates tested
were able to reduce reactivity of the 7E11-C5 MAb.
5. Treatment of the 7E11-C5 antigen with organic
solvents.

Organic solvents can be used to solubilize

hydrophobic membrane proteins and extract the glycolipid
fraction from tissue homogenates.

Various solvents were

tested for their effects on the 7E11-C5 antigen and the
results (Table X) showed that the antigen reactivity was
reduced by some solvents, such as chloroform, acetic acid
and phenol.
6. Glycolipid.

In order to determine whether or not

the 7E11-C5 antigen was glycolipid in nature, chloroformmethanol glycolipid fractions were extracted from LNCaP
tissue homogenates and tested for 7E11-C5 antigen activity.
Radioimmunoassay results gave a negative result (data not
shown) and TLC and TLC immunoblots (Figure 16) further
confirmed that the 7E11-C5 antigen was not demonstrable in
glycolipid extracts of LNCaP tissue.
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TABLE IX
Competitive Blocking of 7E11-C5 MAb to its Target Antigen
with Carbohydrates or Carbohydrate Conjugates3
Carbohydrate0

MW

Concentration

% control binding13
crude Ag pure Ag

galactose

180.2

0.125 M
0.25 M
0.5 M

98
100
100

102
100
117

galNAc

221.2

0.125 M
0.25 M
0.5 M

99
102
98

107
108
96

glcNAc

221.2

0.1 M

87

99

melibiose

360.3

0.1 M

100

95

D-mannose

180.2

0.1 M

91

89

lactose

360.3

0.1 M

90

109

L-fucose

164.2

0.1 M

96

100

D-glucose

180.2

0.1 M

NTd

106

stachyose

666.6

0.1 mg/ml
1 mg/ml

NT
NT

102
110

lacNAc

383.4

0.1 mg/ml
1 mg/ml

NT
NT

94
89

D-raffinose

594.5

0.1 mg/ml
1 mg/rol

NT
NT

96
95

beta-D-gal(1-3)-D-galNAc

383.4

0.1 mg/ml
1 mg/ml

NT
NT

83
94

a The carbohydrate or carbohydrate conjugate was incubated
with an equal volume of the 7E11-C5 MAb at room temperature
for 2 hours and PBS was used as control. A radioimmunoassay
was then performed using 50 {il of the mixture as primary
antibody.
b crude Ag, LNCaP tissue extracts; pure Ag, immunoaffinity
purified antigen.
c galNAc, N-acety1-D-galactosamine; glcNAc, N-acetyl-Dglucosamine; lacNAc, N-acetyllactosamine; beta-D-gal” (l-3)D-galNAc, 2-acetamido-2-Deoxy-3-0-beta-D-galactopyranosyl-Dgalactopyranose.
° NT, not tested.
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TABLE X
Treatment of the 7E11-C5 Antigen with Organic Solvents3
Percentage

% control binding

Chloroform

100

45

Acetic acid

50
100

31
29

Aqueous phenol

100

9

Formamide

50
100

90
58

44
88

70
96

Dimethylformamide

50
100

93
79

n-Butanol

100

77

Pyridine

50
100

66
95

Methanol

50
100

100
89

Solvent

Formic acid

3 The remaining 7E11-C5 antigen activity was tested by a
radioimmunoassay after the antigen (LNCaP tissue extract)
was treated with organic solvents at room temperature for 2
hours. PBS was used as control.
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B
SF:
G M1

GT1b

1

2

3 4

1 2

3 4

Figure 16. Thin-layer chromatography (TLC) and TLC
immunoblot of LNCaP glycolipid extracts.

TLC plates coated

with silica gel were run in a solvent containing
chloroform/methanol/water 5:4:1.

Panel A: TLC immunoblot

results and panel B: visualized TLC results.

The numbered

lanes contained the following samples: lane 1 . tissue
membrane protein 5 /ig/lane as positive control; lane 2 . the
upper layer glycolipid extracts 20 /ig/lane; lane 3 . the
lower layer glycolipid extracts 20 fig/lane; lane 4 .
glycolipid standard control (gangliosides) 20 Mg/lane.
origin; SF, solvent front;

trisialoganglioside lb;

GMl» monosialoganglioside 1.
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7.

Immunoprecipitation.

Immunoprecipitation of the

7E11-C5 antigen was tried using several modified procedures.
LNCaP cultured cells metabolically labeled with 35Smethionine showed little positive signal in the crude LNCaP
cell lysate (data not shown), suggesting that 35S-methionine
was unable to be incorporated by cultured LNCaP cells.
Immunoprecipitation experiments failed to provide meaningful
information after several attempts and using several
modified procedures.

D.

Detection of the 7E11-C5 antigen in serum samples.
1.

Western blot analysis of serum samples.

Forty-eight

serum specimens were analyzed by Western blot analysis.
Eight samples from each of six categories, including normal
males age 50 years or older, BPH patients (biopsy proven)
and CaPpatients (stages A, B, C and D,
tested.

biopsy proven)

were

Table XI describes the sources of the various

samples tested, relevant clinical information and
corresponding PSA values.

Figure 17 shows the Western blot

analysis of the serum samples.

Compared to the positive

control

(LNCaP tissue extract, lane A ) ,none of the 48 serum

samples

showed clear positive bands, i. e. the 100-Kd

70-Kd bands (Figure 17).

and

There were some higher molecular

weight bands observed in some samples, but theses bands were
also identified on the antibody isotype-matched (normal
mouse IgGl) control blot (Figure 18, B).

Therefore, they
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TABLE XI
Serum Samples Analyzed by Western Blota
Sample
code

Sample
type

1
2
3
4
5
6
7
8

0201
0206
0221
0225
0231
0250
0269
0271

N
N
N
N
N
N
N
N

9
10
11
12
13
14
15
16

5189
5191
5192
5193
5194
5195
5196
5197

BPH
BPH
BPH
BPH
BPH
BPH
BPH
BPH

17
18
19
20
21
22
23
24

4955
4956
4958
4960
4961
4962
4963
4964

CaP
CaP
CaP
CaP
CaP
CaP
CaP
CaP

A
A
A
A
A
A
A
A

25
26
27
28
29
30
31
32

4988
4989
4991
4992
4995
4997
4998
5032

CaP
CaP
CaP
CaP
CaP
CaP
CaP
CaP

B
B
B
B
B
B
B
B .

33
34
35
36
37
38
39
40

5143
5171
5172
5173
5174
5176
5177
5179

CaP
CaP
CaP
CaP
CaP
CaP
CaP
CaP

C
C
C
C
C
C
C
C

Case

Stage

WD

Gradeb
MD

PD

PSA
ng/ml
<
<
<
<
<
<
<
<

malec
male
male
male
male
male
male
male

4.0
4.0
4.0
4.0
4.0
4.0
4.0
4.0
2.4
2.8
4.0
1.7
6.7
6.7
4.3
12.9
4.3
21.2
3.0
0.6
11.2
41.0
13.2
18.5

X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X

continuing on next page
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17.6
10.3
1.2
21.5
2.5
4.3
7.2
52.2
5.0
69.5
1.8
79.4
76.8
229.0
111.0
345.0
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TABLE XI (cont.)

Case

Sample
code

41
42
43
44
45
46
47
48

5017
5033
5039
5045
5058
5064
6065
5066

Sample
type

Stage

CaP
CaP
CaP
CaP
CaP
cap
CaP
CaP

D
D
0
D
D
D
D
D

WD

Grade
MD

PD
X

X
X
X
X
X
X
X

PSA
ng/ml
20.9
329.0
32.7
21.8
13.8
15.4
1,540.0
6,246.0

a All diagnoses were pathologically proven and all
patients were previously untreated when the sera were
donated.
b WD, well differentiated? MD, moderately differentiated;
PD, poorly differentiated.
c N male, normal male'.

All were over 50 years old.
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Figure 17. Western blot analysis: Detection of the 7E11-C5
antigen in serum samples.

The serum samples were subjected

to 10% SDS-PAGE, 4 ^il/lane.

The separated proteins were

transferred to Immobilon-P membrane and analyzed for
reactivity to 125I-labeled 7E11-C5 MAb.

Lane A was loaded

with 80 ng protein of LNCaP tissue extracts as positive
control.
Grade3
MD

PSA
ng/ml

Sample
code

Sample
type

B

0201

N male*3

< 4.0

C

0206

N male

< 4.0

D

5196

BPH

4.3

E

5197

BPH

12.9

F

4955

CaP

A

X

4.3

G

4956

CaP

A

X

21,2

H

4998

CaP

B

X

7.2

I

5032

CaP

B

J

5177

CaP

C

X

111.0

K

5179

CaP

C

X

345.0

L

6065

CaP

D

M

5066

CaP

D

Lane

Stage

WD

PD

52.2

X

1,540.0

X
X

6,246.0

a WD, well differentiated? MD, moderately differentiated;
PD, poorly differentiated. All diagnoses were
pathologically proven and all patients were previously
untreated when the sera were donated.
k N male, normal male.

Both were over 50 years old.
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Figure 18. &, Western blot analysis of serum samples from
normal female, normal male, BPH and CaP patients with 7E11C5 MAb.
Ml/lane.

The serum samples were subjected to 10% SDS-PAGE, 4
The separated proteins were transferred to

Immobilon-P membrane and analyzed for reactivity to 125Ilabeled 7E11-C5 MAb.

Lane 1 was loaded with 80 /ig protein

of cultured LNCaP cell extract as a positive control.

fi,

Western blot of the same samples as for &, but reacted with
an isotype-matched negative control antibody (125I-labeled
normal mouse IgGl).

Both blots were exposed to X-ray film

for 14 days.

Sample
code

Sample
type

2

5221

N female*3

3

0201

N malec

4

5196

BPH

5

4955

CaP

Lane

Stage

WD

Grade3
MD

PD

PSA
ng/ml

< 4.0
4.3
A

X

4.3

3 WD, well differentiated; MD, moderately differentiated;
PD, poorly differentiated. All diagnoses were
pathologically proven and all patients were previously
untreated when the serum was obtained.
b N female, normal female.
c N male, normal male.

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited without p erm ission.

67

A

B

Kd
200* 100 * 70*-

1 2

3 4
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were not considered to be 7E11-C5 antigen.
2.

Detection of the 7E11-C5 antigen in serum samples by

a competitive binding radioimmunoassay.

A modified

competitive binding immunoassay was used to detect the 7E11C5 antigen in serum samples.

The samples were from normal

female, normal male, BPH and all grades of CaP and two to
five samples from each category were tested.

The results

(Table XII) showed that the percent inhibition was between
52% to 65% with no significant differences regardless of the
serum category.
positive results.

Even female serum samples showed similar
In an attempt to increase the specificity

of the immunoassay, a direct inhibition assay, instead of
indirect inhibition assay, was used to test the serum
samples.

Table XIII shows that the percent inhibition was

similar for both assays.

The results obtained by the

competitive inhibition assays together with the Western blot
analysis suggest that other molecules, instead of the 7E11C5 antigen, may nonspecifically interfere with the 7E11-C5
MAb, resulting in the high percent of inhibition.
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TABLE XII
Detection of the 7E11-C5 Antigen in Serum Samples
by Direct Inhibition Assaya
Sample Sample
code
type

Stage

4912
4914

N female0
N female

0201
0202
0204
0206
0207

N
N
N
N
N

WD

Grade*3
MD

PD

PSA
ng/ml

7E11-C5
inhibition %
55.3
56.5

4.0
4.0
4.0
4.0
4.0

65.6
61.8
58.6
59.9
64.5

2.4
2.8
4.0
1.7
6.7

55.3
59.1
54.4
61.0
59.3

21.2
41.0
0.9
0.5
30.6

54.2
62.0
58.0
54.4
56.8

17.6
10.3
1.2
21.5
52.2

60.4
58.9
56.0
56.0
53.1

X
X

66.1
1.8
79.4
229.0
345.0

52.0
58.7
57.0
63.2
59.7

X

329.0
13.8
1,540.0
6,246.0
415.0

49.2
58.4
61.3
58.5
56.0

<
<
<
<
<

male**
male
male
male
male

5189
5191
5192
5193
5194

BPH
BPH
BPH
BPH
BPH

4956
4962
4965
4969
4973

CaP
CaP
CaP
CaP
CaP

A
A
A
A
A

4988
4989
4991
4992
5032

CaP
CaP
CaP
CaP
CaP

B
B
B
B
B

4751
5172
5173
5176
5179

CaP
CaP
CaP
CaP
CaP

C
C
C
C
c

5033
5058
5065
5066
5068

CaP
CaP
Cap
CaP
CaP

D
D
D
D
D

X
X
X
X
X
X
X
X
X
X
X
X

X
X
X
X

continuing on next page
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% Inhibition: normal female — 55.9 + 0.6 SD
Normal male
BPH

=

62.1

2.7 SD

57.9 + 2.6 SD

CaP stage A = 57.1 + 2.9 SD
CaP stage B = 56.9 ± 2.6 SD
CaP stage C = 58.1 + 3.7 SD
CaP stage D

56.7 + 4.1 SD

a The serum samples were tested by 7E11-C5 MAb inhibition
assay as described in "Materials and Methods". All
diagnoses were pathologically proven and all patients were
previously untreated when the sera were donate.d.
k WD, well differentiated; MD, moderately differentiated;
PD, poorly differentiated.
c N female, normal female.
^ N male, normal male.

All were over 50 years old.
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TABLE XIII
Detection of the 7E11-C5 Antigen in Serum Samples by
Direct and Indirect Inhibition Assays
Sample
code
0207

Sample
type
Stage
N male*3

PSA
ng/ml

7E11-C5 inhibition %a
direct assay indirect assay

< 4.0

41.5

49.8

2.4

39.4

56.0

5189

BPH

4962

CaP

A

41.0

38.3

51.2

5065

CaP

D

1,540.0

43.0

57.5

a Indirect competitive inhibition assay was described in
"Materials and Methods", and in the direct assay, 125ilabeled 7E11-C5 MAb was used instead of unlabeled 7E11-C5
MAb and
I-labeled rabbit anti-mouse antibody. All
diagnoses were pathologically proven and all patients were
previously untreated when the serum was obtained.
k N male, normal male, over 50 years old.
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CHAPTER IV

DISCUSSION

Carcinoma of prostate (CaP) is the most common cancer
in men, with well over 100,000 cases diagnosed in the United
States in 1990.

In nearly two thirds of the cases, the

tumor had already spread beyond the prostate at the time of
diagnosis.

Since early-stage CaP can be effectively treated

with radical prostatectomy and radiation therapy, early
detection is essential in curbing CaP mortality (1-9).
The 7E11-C5 MAb described by Horoszewicz et aJL. (43),
recognizes a prostate organ-specific antigen.

^^Tn-labeled

7E11-C5 MAb has been shown to specifically localize in LNCaP
tumors grown in nude mice (46) and in preliminary clinical
investigations, 113Tn-labeled 7E11-C5 MAbs were also used to
image human CaP metastases (90).

In addition, the MAb was

reported to detect shed 7E11-C5 antigen in the serum of
patients with CaP (43).

The previous report suggested that

patients with positive serum levels were more likely to have
progressive disease than those who had normal levels of
7E11-C5 antigen expression (43).

If these results could be

verified, the 7E11-C5 antigen might be clinically useful for
identifying CaP patients most likely to have a poor
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prognosis and who night be candidates for nore aggressive
treatment.

The objectives of the present study were

undertaken to further determine the specificity of the 7E11C5 antigen and to purify and biochemically characterize the
antigen.
The previous 7E11-C5 MAb specificity studies (43) were
carried out by immunohistochemical techniques (i. e.
immunoperoxidase staining of tissue sections).

In the

present study, further evaluation of the specificity of the
MAb 7E11-C5 was determined by Western blot analysis of
extracts of LNCaP xenograft and human tissues and
competitive binding experiments.

Western blot analysis

showed the presence of a 100-Kd band and a 70-Kd band in
tissue extracts of LNCaP, normal prostate, BPH and CaP.
Similar bands were detected in pooled normal seminal plasma,
but not in any of the non-prostate tissue extracts tested.
Since these bands were present under reducing conditions, it
suggested the 7E11-C5 antigen consisted of two peptide
chains.

A competitive binding-inhibition study showed that

antibodies to other prostate-associated antigens were unable
to block the binding of 7E11-C5 MAb to its target antigen.
Molecular weight comparisons, by Western blot, demonstrated
that there was no similarity between the 7E11-C5 antigen and
the other three major prostate-associated antigens, PAP, PSA
and PSP.

These results strongly indicate that the 7E11-C5

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited w ithout p erm ission.

74

antigen is a prostate organ-specific antigen and distinct
from other known major prostate antigens (87-89).
The prostate organ-specific markers, PSA and PAP,
particularly PSA, have been used clinically to provide both
diagnostic and prognostic information about CaP.

PSA has

been considered to be the best overall serum marker for CaP,
and some investigators even consider PSA to be the most
meaningful and useful tumor marker available in cancer
biology (91).

However, the usefulness of PSA by itself as a

marker for early detection and screening has at least two
limitations.

First, PSA is not prostate cancer-specific; it

is prostate organ-specific, and numerous benign prostatic
conditions can influence serum PSA levels.

For example, 25%

to 30% of men with BPH and without evidence of CaP had an
elevated serum PSA level (17, 92).

Second, not all CaP

patients have an elevation in their serum PSA levels.

In

fact, 38% to 45% of men with CaP have serum PSA levels in
the normal range (0 to 4 ng/ml)

(92-96).

A goal of the

present study was to determine whether or not the 7E11-C5
marker can provide any additional diagnostic or prognostic
information in the management of CaP.

Hopefully, a multiple

marker system will provide more accurate information for CaP
than presently available.
The major objectives to reach this goal were to purify
and characterize the 7E11-C5 antigen.

Since the LNCaP cell

line was the immunogen for generating the hybrid secreting
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the 7E11-C5 MAb, LNCaP xenograft tissue homogenates were
used as the source of crude antigen.

The tissue homogenates

were a mixture of all cell organelles with heterogeneity in
both size and density.

Partial separation of membrane

proteins could be achieved on the basis of their density;
with increasing centrifugal force, the cell debris, nuclei,
mitochondria, lysosomes and microsomes can be sedimented in
that order (97).

In the present study, the preparation of

LNCaP tissue extracts was based on this principle.

Since

the 7E11-C5 antigen is an insoluble, membrane-bound
glycoprotein, the first low speed spin was, therefore,
designed to remove the cell debris, nuclei and mitochondria
and the second high speed and longer centrifugation was used
to concentrate the membrane-bound proteins in a pellet by
removing the soluble molecules (42).
Proteins are fragile molecules that require care during
purification to ensure that they remain intact and fully
active.

Therefore, in order to minimize proteolysis and

prevent protein denaturation from endogenous proteases in
the LNCaP tissue homogenate, a protease inhibitor cocktail,
including antipain, EDTA and pepstatin, was used in the
study and the procedures were performed at low temperature
(4*C)

(98).
Unlike PAP, PSA and PSP, the 7E11-C5 antigen is a

cytoplasmic, insoluble glycoprotein complex, which
complicates purification.

Before classical techniques of
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biochemical purification could be applied, the antigen had
to be converted into a soluble form.

Detergents are most

commonly employed for solubilizing membrane proteins.

The

detergents used in solubilization schemes can be divided
into three classes: (1) non-ionic detergents, such as NP-40
and glucoside; (2) zwitter-ionic detergents, such as CHAPS;
and (3) ionic detergents, such as SDS.

The choice of a

detergent is determined by several factors, such as
efficiency of solubilization, preservation of biological
activity of the membrane protein and requirements for
further purification procedures.

The choice of detergent

for membrane protein solubilization in immunoaffinity
chromatography is restricted to those of a non-denaturing
species because the denaturing reagents may damage the
antibodies coupled to the gel matrices (56, 57).

In the

present study, the non-ionic detergent, NP-40, was found to
be the most effective detergent for solubilizing the 7E11-C5
antigen from extracts of LNCaP cells and LNCaP xenografts.
Organic solvent extraction procedures are also useful
procedures for solubilizing membrane proteins containing
proteolipids.

Organic solvents, however, tend to cause

protein denaturation and are not recommended if the
biological activity of the membrane protein needs to be
preserved.

The compatibility between the solvents and

further purification steps also needs to be considered.
the present study, a group of organic solvents was tested
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and the result showed that the antigen was sensitive to some
of the solvents tested (Table X).

However, considering that

further purification by immunoaffinity chromatography, after
solubilization, may be required, and not knowing the
interaction of the organic solvents and the 7E11-C5 MAb
coupled to the support matrix, organic solvents were not
considered as good candidates for the solubilization step
(58, 59).
Attempts to purify the solubilized antigen by molecular
exclusion chromatography were unsuccessful.

Gel filtration

chromatography showed that all the 7E11-C5 antigen activity
appeared in the void volume, using either Sephadex G-100,
Sephadex G-200 or Sephacryl S-300 columns.

Failure of the

antigen to be separated by Sephacryl S-300 chromatography
(fractionation range MW 10,000-1,500,000) suggested that
after detergent solubilization, the size or shape of the
antigen might be changed (size increased or globular shape
changed to thread-like shape), causing ineffective
separation of the antigen (60).
Some prostate-associated antigens such as PAP, PSA and
PSP have been successfully purified by ion exchange
chromatography (14, 26, 99).

However, ion exchange

chromatography was unsuccessful in separating the 7E11-C5
antigen from contaminating proteins.

The eluted 7E11-C5

antigen was spread throughout the entire separation run.
this case, the eluted antigen had low antigen reactivity,
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suggesting a heterogeneous surface charge developed on the
antigen after detergent solubilization.
After failure to effectively separate the 7E11-C5
antigen by molecular exclusion chromatography and ion
exchange chromatography, an attempt to purify the antigen by
immunoaffinity chromatography was performed.

Immunoaffinity

chromatography is one of the most powerful techniques for
the isolation of proteins.

The preparation of solid-phase

gel-linked antibodies involves both activation of the gel
and coupling of antibody to the gel.

This coupling should

be highly efficient and the antibody must remain
biologically active.

In the present study, the gel matrix

was cross-linked with amino groups of the 7E11-C5 MAb via
the aldehyde reaction.

The aldehyde group of the matrix (R-

CHO) reacted with the amino group of the MAb (R'-+NH 3 ),
removing one molecule of water and forming reversible Schiff
base (R-CH^NH-R').

Under reducing condition (NaBH3 CN), the

Schiff base became a stable covalent linkage between the
matrix and the MAb (R-CH-+NH 2 ~R') (100).

The advantages of

this type of coupling are high coupling efficiency (> 80%
for 7E11-C5 MAb) and stable linkage of immobilized MAb and
matrix.

The disadvantage of this coupling system, however,

is that the matrix randomly binds to the amino group of the
antibody, so that after the coupling, not all the MAb
molecules are optimally oriented for antigen binding (62).
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Because antigenicity needs to be maintained, elution
conditions should be as gentle as possible.

An ideal

elution buffer should yield a sharp peak with complete
release of the antigen without damaging the antigen and the
antibody.

In the present study, an elution buffer

consisting of 2 M MgCl2 was found to be the most effective
buffer for eluting the 7E11-C5 antigen from the
immunoaffinity column.
Western blot analysis indicated that the eluate from
the immunoaffinity column consisted of two bands on SDSPAGE, the 100-Kd band and a smaller (45-Kd) band.

The

smaller band was considered to represent possible
degradation of the antigen.

Although a single 7E11-C5

reactive fraction was obtained by immunoaffinity
chromatography, silver staining showed that there were
several bands present on SDS-PAGE gel (Figure 12, B),
suggesting that the antigen might not be totally pure.
HPLC molecular exclusion chromatography was used to
further purify the antigen resulting in a single antigen
reactive fraction, which was about 500-Kd in molecular
weight.

The 500-Kd molecular weight of the 7E11-C5 antigen

under native condition open the possibility of that the
antigen might consists of three monomers united by noncovalent bonds.

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited without p erm ission.

80

The HPLC purified antigen was analyzed for N-terminal
amino acid sequence and amino acid composition, but the
results were inconclusive.

Because the antigen was

insoluble, the majority of the antigen became insoluble
again during the purification procedures (removing the
detergent), making it difficult to obtain an adequate amount
of the antigen for sequencing.

Efforts to overcome this

problem will be required before amino acid analysis can be
successful.

One possible approach would be to "capture" the

antigen on a nitrocellulose membrane.

The membrane with the

specific 7E11-C5 antigen active band(s) could then be
directly analyzed for sequencing.
Biochemical and immunological characterization of the
antigen was carried out with both crude and purified 7E11-C5
antigen.

Experiments using the purified molecule are

recommended, because it is sometimes difficult to rule out
the indirect effect from other contaminating components in
the sample mixture (102).

In this study, experiments using

both antigen sources gave similar results.

Some

investigators have reported that chemical treatment might
interfere with the ability of the antigen to adhere to a 96well assay plate, therefore, Western blot analysis, rather
than radioimmunoassay, was recommended (103).

In the

present study, experiments were carried out primarily using
the modified radioimmunoassay procedures and selected
samples also were analyzed by Western blot.

Both
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experiments yielded similar results, which confirmed the
reliability of the radioimmunoassay procedures.
Periodate oxidation is a common procedure for
structural analysis of glycoproteins and has been used to
elucidate the participation of the carbohydrate moiety in
the biological activity of glycoproteins (104).
is a strong oxidizing reagent.

Periodate

A low concentration (< 10

mM) can destroy the carbohydrate determinant without
altering the protein or lipid component, while high
concentrations can be destructive to peptide chains (65,
105, 106).

The present study showed that the 7E11-C5

antigen was sensitive to periodate treatment (Table V and
Figure 14, lane J).

The antigen was also sensitive to

protease treatments, indicating that the 7E11-C5 antigen was
a glycoprotein and that both carbohydrate and peptide were
required for its antigenicity.
Enzymatic deglycosylation is also commonly used to
study the specific sugar residue involvement in the
glycoprotein molecule.

Glycosidases specifically hydrolyze

carbohydrates from glycopeptides or glycoproteins and
release the free sugar residue.

Such treatment of the 7E11-

C5 (Table VII and Figure 15) showed that the 7E11-C5 antigen
was sensitive only to beta-galactosidase.

Galactosidase

catalyzes the release of galactose residue from galactose
conjugates, thereby suggesting that galactose is a major
component of the 7E11-C5 antigenic determinant.
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Lectins are proteins or glycoproteins derived primarily
from plants which can bind to specific carbohydrate groups
on cells.

A lectin competition assay was used to determine

which carbohydrate(s) were involved in the 7E11-C5 antigenic
determinant.

The result of this experiment (Table VIII)

showed that only the galactose-binding lectins (MPA and PNA)
and N-acetyl-D-galactosamine-binding lectins (DBA and SBA)
were able to block the binding of MAb 7E11-C5 to its target
antigen, suggesting that both galactose and galNAc were
involved in the 7E11-C5 antigenic determinant.
Carbohydrate competitive binding experiments showed
that free carbohydrates or carbohydrate conjugates,
including galactose and galNAc, were unable to block the
antigen-binding site of the 7E11-C5 MAb.

These results

suggested that the size of the blocking carbohydrate
molecules were not large enough to efficiently occupy the
binding site, even though some larger aminosugars were
tested (Table IX), or that the 7E11-C5 MAb had much higher
affinity for the intact target antigen (a glycoprotein
complex) than the sugar residue alone.
Metabolic labeling experiments suggest that 35 smethionine was not metabolically incorporate into proteins
in cultured LNCaP cells.

This might occur if the percentage

of methionine in the 7E11-C5 molecule was low.

This is

substantiated by tentative results of the amino acid
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composition analysis which showed that only 0.6% methionine
was present in the 7E11-C5 antigen (data from the Protein
and Nucleic Acid Sequence Center at the University of
Virginia).

Another possible reason for the low

incorporation of 35S-methionine might be due to the low
metabolic rate of cultured LNCaP cells (doubling time is 72
hours in vitro)

(44).

Horoszewicz et al. reported that the 7E11-C5 antigen
was shed in the serum of patients with CaP (43).

In the

present study, Western blot analysis and 7E11-C5 MAb
inhibition assays were used in an attempt to detect the
7E11-C5 antigen in serum.

A total of 48 serum samples from

normal male, BPH and all grades of CaP were analyzed by
Western blot and the results did not confirm the presence of
the 7E11-C5 antigen in serum samples, even those from CaP
patients with advanced disease.

Although there were some

high molecular weight bands in the serum samples blot
(Figure 17), the result from an isotype-matched negative
antibody control indicated that those bands were nonspecific
(Figure 18, B).

There are approximately 75 ftg of protein

per microliter in normal adult serum (107) and the
sensitivity of Western blot analysis was reported to be 1 ng
protein/band (77).

In the present study, 4 jtl serum (about

300 fig serum protein) were added to each lane of SDS-PAGE
gel.

If the 7E11-C5 antigen does exist in serum samples,

the concentration must be extremely low.
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Horoszewicz et al. tested serum samples using an
inhibition ELISA with LNCaP cells as the target antigen and
reported that the 7E11-C5 antigen was shed primarily in sera
from advanced stage CaP patients.

In the present study, a

modified inhibition radioimmunoassay using immunoaffinity
purified antigen was used to test for the presence of
antigen in serum, but again, the results could not confirm
the previous report.

In the present study the percent

inhibition was high (52%-65%) regardless of the type of
serum analyzed and there was no discrimination among the
groups (Table XII).

Normal female serum samples also showed

similar positive results.

In order to increase the

specificity of the result, a direct inhibition assay,
instead of a indirect inhibition assay, was used to measure
the serum samples.

The results from the two assays were

similar (Table XIII).

Considering the negative results

obtained by Western blot, these high inhibition results
suggest that molecules, other than the 7E11-C5 antigen,
might have nonspecifically blocked the binding of the 7E11C5 MAb.
Because the sensitivity of the inhibition assay used in
the present study was limited (108, 109), failure to
identify the 7E11-C5 antigen in the serum samples does not
necessarily mean that there is no clinical significance for
this prostate tumor-associated marker.

A more sensitive

double-determinant immunoassay may be required to accurately
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measure the 7E11-C5 antigen levels in serum and other body
fluids.

Development of a sensitive assay may also require

the use of high affinity MAbs to at least two different
epitopes on the 7E11-C5 antigen.
This study has provided important information regarding
the biochemical and immunochemical nature of the target
antigen recognized by MAb 7E11-C5.

The inability to obtain

adequate yields of purified antigen suggests that the 7E11C5 antigen is tightly bound to cellular components highly
resistant to standard solubilization procedures.

The data

also suggest that the antigen is unstable in a high salt
environment.

Because of the insoluble and unstable nature

of the 7E11-C5 antigen and the low antigen yield obtained
from cultured LNCaP cells and LNCaP xenograft, alternative
approaches will be necessary to obtain adequate quantities
of pure antigen needed for amino acid sequence analysis and
the subsequent preparation of synthetic peptides or to
isolate the cDNA clone and produce recombinant 7E11-C5
antigens.

These forms of the antigen could then be used for

more definitive biochemical characterization of the 7E11-C5
antigen, to prepare second generation antibodies for epitope
characterization, and to develop a sensitive 2-site
radioimmunoassay.
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